Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | CDC25B | P30305 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | PTPRC | P08575 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | APAF1 | O14727 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | GALK1 | P51570 | 3/20 | 0.52 |
| ▸ | BLM | P54132 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | S100A4 | P26447 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | TDP2 | O95551 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13487417 | 0.95 | PTPRC (0.59) | MEN1KMT2ACDC25BPTPN1PTPRC | |
| SCHEMBL181722 | 0.95 | PTPRC (0.55) | MEN1KMT2ACDC25BPTPN1PTPRC | |
| SCHEMBL29390818 | 0.95 | PTPRC (0.55) | MEN1KMT2ACDC25BPTPN1PTPRC | |
| SCHEMBL3894758 | 0.93 | MEN1 (0.57) | MEN1KMT2ACDC25BPTPN1PTPRC | |
| SCHEMBL30886642 | 0.91 | PTPRC (0.60) | MEN1KMT2ACDC25BPTPN1PTPRC | |
| SCHEMBL13487409 | 0.91 | PTPRC (0.60) | MEN1KMT2ACDC25BPTPN1PTPRC | |
| SCHEMBL9811010 | 0.91 | CA1 (0.48) | PTPN1PTPRCMAPTNPC1RAB9A | |
| SCHEMBL4322090 | 0.91 | CA1 (0.52) | MEN1KMT2ACDC25BPTPN1MAPT | |
| SCHEMBL9856229 | 0.88 | GPR3 (0.54) | MEN1KMT2APTPN1PTPRCMAPT | |
| SCHEMBL30479662 | 0.85 | CA1 (0.52) | PTPN1PTPRCS100A4MAOAUSP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655264-B2 | Metallocene compounds, and preparation and use thereof for synthesis of poly-alpha-olefins as lubricating base oil | APALENE TECHNOLOGY CO., LTD. (HANGZHOU) (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11512204-B2 | Squarylium dye and composition containing same | TOYO INK SC HOLDINGS CO., LTD. (JP) | 2022-11-29 | — | — | US | disclosed |
| CN-113652705-B | Method for synthesizing fluorenone through catalytic electrolysis of N-hydroxyphthalimide | 北京工业大学 | 2022-07-22 | — | — | CN | disclosed |
| CN-113652705-A | Method for synthesizing fluorenone by catalyzing and electrolyzing N-hydroxyphthalimide | 北京工业大学 | 2021-11-16 | — | — | CN | disclosed |
| US-20200115556-A1 | SQUARYLIUM DYE AND COMPOSITION CONTAINING SAME | TOYO INK SC HOLDINGS CO., LTD. (JP) | 2020-04-16 | — | — | US | disclosed |
| US-20180258112-A1 | Metallocene compounds, and preparation and use thereof for synthesis of poly-alpha-olefins as lubricating base oil | APALENE TECHNOLOGY CO., LTD. (JIAXING) (CN) | 2018-09-13 | — | — | US | disclosed |
| EP-2423176-A1 | CARBOXYLIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| EP-0886182-A1 | Positive photoresist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0092385-B1 | HYDANTOIN DERIVATIVES FOR USE IN INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOREN COMPOUNDS | ALCON LABORATORIES, INC. (US) | 1991-06-12 | — | — | EP | disclosed |
| US-4820800-A | Arylene sulfide polymers | PHILLIPS PETROLEUM COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| US-4540700-A | Treatment of diabetic complications with certain spiro-imidazolidine-diones | ALCON LABORATORIES, INC. (US) | 1985-09-10 | — | — | US | disclosed |
| US-4438272-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1984-03-20 | — | — | US | disclosed |
| US-4436745-A | TETRACYCLIC SPIROHYDANTOINS | ALCON LABORATORIES, INC. (US) | 1984-03-13 | — | — | US | disclosed |
| WO-1983003543-A1 | METHOD OF INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOROFLUOREN AND SPIRO-DIFLUOROFLUOREN COMPOUNDS | ALCON LAB INC (US) | 1983-10-27 | — | — | WO | disclosed |
| EP-0092385-A2 | Hydantoin derivatives for use in inhibiting aldose reductase activity, compositions therefor and process for preparing spiro-fluoren compounds | ALCON LABORATORIES, INC. (US) | 1983-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | GPR119, GPR65, GPR55 | MEN1 2027/4885KMT2A 2161/4885CDC25B 3484/4885 |
| US-11655264-B2 | Metallocene compounds, and preparation and use thereof for synthesis of poly-alpha-olefins as lubricating base oil | POLM, POLA1, POLD1 | MEN1 876/4885KMT2A 3067/4885CDC25B 2699/4885 |
| US-20180258112-A1 | Metallocene compounds, and preparation and use thereof for synthesis of poly-alpha-olefins as lubricating base oil | POLM, POLA1, POLD1 | MEN1 876/4885KMT2A 3067/4885CDC25B 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.